Navigation Links
China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2013 Financial Results
Date:2/19/2013

HONG KONG, Feb. 19, 2013 /PRNewswire-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) (the "Company") today announced its plan to release financial results for the third quarter and first nine months of fiscal year 2013 on Tuesday, February 26, 2013, after market close in the US. 

The Company will host a conference call at 8:00 a.m. ET on Wednesday, February 27, 2013 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session.  Interested parties may access the audio webcast through the Company's IR website at http://ir.chinacordbloodcorp.com.  A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above.  Listeners may also access the call by dialing 1-718-354-1231 or 1-866-519-4004 for US callers or +852-2475-0994 for Hong Kong callers, access code: 90798569. 

Please dial in ten minutes prior to the conference call to ensure proper connection, and be prepared to provide your name and company name to the operator.

Supplemental financial information referenced in the conference call and the third quarter fiscal 2013 earnings press release will be available at http://www.chinacordbloodcorp.com, in the section titled Investor Center/Press Release, after 4:00 p.m. ET on Tuesday, February 26, 2013 and in the Company's Report on Form 6-K for the month of February 2013 available on the Securities and Exchange Commission's website at www.sec.gov.  

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.  Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today.  China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.  For more information, please visit the Company¡¦s website at http://www.chinacordbloodcorp.com.  

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com

ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516
U.S. Tel: (646) 405-5185
Email: robert.koepp@icrinc.com


'/>"/>
SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
2. Infectious Immunology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
3. Lucintel’s Analysis of Growth Opportunities in China’s Composites Industry: Expect Market to Surpass $11 Billion in 2017
4. China Cord Blood Corporation to Further Consolidate its Corporate Structure
5. Biomaterials China News 1210 - Annual Subscription
6. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2013
7. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
8. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
9. China Biologic Products to Report Third Quarter 2012 Financial Results
10. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
11. China Cord Blood Corporation and Golden Meditech Holdings Limited Enter into Convertible Note Financing to Further Expand Cord Blood Banking Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2016)... ... May 22, 2016 , ... Doctors in Rome say micronutrients ... asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article on the new ... of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more than 150 studies ...
(Date:5/19/2016)... , ... May 19, 2016 , ... Anton Paar USA, ... square foot office building is complete. The new structure adds a third office building ... Anton Paar USA purchased 2.4 acres of land, along with office space adjacent ...
(Date:5/19/2016)... - I dati saranno presentati nel ... ° Congresso della Società Americana di Oncologia ... conclusioni dello studio indicano un tasso di risposta del 56% ... presenta una d urata della risposta (Duration Of Response, ... dei pazienti ha riscontrato un beneficio clinico.      ...
(Date:5/18/2016)... Fort Washington, PA (PRWEB) , ... May 18, ... ... and at least 1,200 hospitalizations are a direct result of asthma complications.* Costing ... health challenge across the country. , “For too many, the ...
Breaking Biology Technology:
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... , March 22, 2016 ... research report "Electronic Sensors Market for Consumer Industry by ... & Others), Application (Communication & IT, Entertainment, ... - Global Forecast to 2022", published by ... is expected to reach USD 26.76 Billion ...
Breaking Biology News(10 mins):